RecruitingPhase 2NCT05887609
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Studying Malignant tumor of fallopian tubes
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Principal Investigator
- Bradley Corr, MDUniversity of Colorado, Denver
- Intervention
- Mirvetuximab Soravtansine-gynx(drug)
- Enrollment
- 53 target
- Eligibility
- 18-100 years · FEMALE
- Timeline
- 2023 – 2031
Study locations (5)
- University of Colorado Hospital, Aurora, Colorado, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- UPMC Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States
- University of Wisconsin - Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05887609 on ClinicalTrials.govOther trials for Malignant tumor of fallopian tubes
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07278336A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian CancerAbbVie
- RECRUITINGNANCT06855706An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 StudyRoswell Park Cancer Institute
- RECRUITINGPHASE2NCT06787612Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRegeneron Pharmaceuticals
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT05053750TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerM.D. Anderson Cancer Center